These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35727143)

  • 21. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.
    Huhn GD; Shamblaw DJ; Baril JG; Hsue PY; Mills BL; Nguyen-Cleary T; McCallister S; Das M
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz472. PubMed ID: 31950070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B.
    Shin H; Lim GS; Yoon JW; Ko Y; Park Y; Park J; Hur MH; Park MK; Cho Y; Lee YB; Cho EJ; Kim BH; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Med Virol; 2024 Jul; 96(7):e29760. PubMed ID: 38940453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
    Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV.
    Sekiya R; Muramatsu T; Ichiki A; Chikasawa Y; Bingo M; Yotsumoto M; Hagiwara T; Amano K; Kinai E
    J Infect Chemother; 2023 Feb; 29(2):171-178. PubMed ID: 37589078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.
    Fung SK; Pan CQ; Wong GL; Seto WK; Ahn SH; Chen CY; Hann HL; Jablkowski MS; Kim YJ; Yurdaydin C; Peng CY; Nguyen T; Yatsuhashi H; Flaherty JF; Yee LJ; Abramov F; Wang H; Abdurakhmanov D; Lim YS; Buti M
    Aliment Pharmacol Ther; 2024 Jan; 59(2):217-229. PubMed ID: 37905449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.
    Darnell J; Jain S; Sun X; Qin H; Reynolds T; Karris MY; Hill LA
    Medicine (Baltimore); 2021 Aug; 100(34):e27047. PubMed ID: 34449491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
    Hsu JY; Sun HY; Chen LY; Chang SY; Chuang YC; Huang YS; Su YC; Liu WC; Hung CC
    J Glob Antimicrob Resist; 2024 Mar; 36():426-435. PubMed ID: 37923129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
    Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
    Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
    Gazzola L; Tagliaferri G; De Bona A; Mondatore D; Borsino C; Bini T; Marchetti G; d'Arminio Monforte A
    HIV Med; 2021 Feb; 22(2):140-145. PubMed ID: 33084173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
    Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
    J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
    Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
    J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
    PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.
    Ritou E; Satta S; Petcherski A; Daskou M; Sharma M; Vasilopoulos H; Murakami E; Shirihai OS; Kelesidis T
    Metabolism; 2023 Apr; 141():155395. PubMed ID: 36842771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.